A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers. (Q54508329)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641219%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641219%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641219%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Joan J Bech-Serra

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641219%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Beatriz Morancho

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641219%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Joaquin Arribas

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641219%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

7

A Pandiella

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641219%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

J L Parra-Palau

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641219%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Y H Ibrahim

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641219%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

C Bernadó Morales

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641219%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

F Canals

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641219%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

I Rubio

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641219%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

J Baselga

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641219%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

language of work or name

English

0 references

publication date

28 May 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641219%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641219%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641219%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641219%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

1452-1459

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641219%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/onc.2012.152

2 February 2020

exact match

0 references

cites work

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.152

The epidermal growth factor receptor: from development to tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.152

EGF-ERBB signalling: towards the systems level

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.152

New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.152

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.152

p95HER2 and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.152

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.152

A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.152

Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.152

A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.152

Caspase-8-dependent HER-2 cleavage in response to tumor necrosis factor alpha stimulation is counteracted by nuclear factor kappaB through c-FLIP-L expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.152

Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.152

Caspase cleavage of HER-2 releases a Bad-like cell death effector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.152

Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.152

Caspase-dependent cleavage of ErbB-2 by geldanamycin and staurosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.152

Identification of proteolytic fragments from ErbB-2 that induce apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.152

On the sequential determinants of calpain cleavage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.152

Protein quality control in the early secretory pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.152

FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.152

Effector and precursor phenotypes of lymphokine-activated killer cells in mice with severe combined immunodeficiency (scid) and athymic (nude) mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.152

The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.152